{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:48:06Z","timestamp":1787503686941,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jaip.2020.02.013","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:56:37Z","timestamp":1582718197000},"page":"1668-1680.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin"],"prefix":"10.1016","volume":"8","author":[{"given":"Jared","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Garcia-Neuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna-Marie","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclden","family":"Pasaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.02.013_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jcf.2009.08.002","article-title":"A\u00a0safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity","volume":"8","author":"Legere","year":"2009","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jaip.2020.02.013_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","article-title":"Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions","volume":"137","author":"Picard","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaip.2016.04.013","article-title":"Chronic rhinosinusitis in patients with cystic fibrosis","volume":"4","author":"Hamilos","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00053-2017","article-title":"Severe asthma: phenotyping to endotyping or vice versa?","volume":"49","author":"Papi","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.02.013_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"L\u00f6tvall","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.02.013_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1378\/chest.15-1511","article-title":"Molecular endotyping of pulmonary fibrosis","volume":"149","author":"Goodwin","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.02.013_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1200\/JOP.2017.022152","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology","volume":"13","author":"Sepulveda","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","article-title":"Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment","volume":"124","author":"Brennan","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","article-title":"A\u00a0protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions","volume":"129","author":"Patil","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib15","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.4049\/jimmunol.178.5.2883","article-title":"Tumor evasion of the immune system by converting CD4+CD25\u2212 T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta","volume":"178","author":"Liu","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib17","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2020.02.013_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11882-008-0011-0","article-title":"Hypersensitivity reactions to oxaliplatin and other antineoplastic agents","volume":"8","author":"Syrigou","year":"2008","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2020.02.013_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","article-title":"Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents","volume":"102","author":"Lee","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib20","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients","volume":"41","author":"Maindrault-Goebel","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaip.2020.02.013_bib21","first-page":"451","article-title":"Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer\u2014identification, prevention, and management","volume":"5","author":"Kang","year":"2007","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.jaip.2020.02.013_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000178163","article-title":"Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience","volume":"76","author":"Polyzos","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.jaip.2020.02.013_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.anai.2015.07.017","article-title":"Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy","volume":"115","author":"Wang","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib24","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jaci.2010.11.046","article-title":"Drug hypersensitivity: pharmacogenetics and clinical syndromes","volume":"127","author":"Phillips","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00128071-200304080-00006","article-title":"Differential diagnosis of severe cutaneous drug eruptions","volume":"4","author":"Bachot","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2020.02.013_bib26","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2020.02.013_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","article-title":"Anaphylaxis\u2014a practice parameter update 2015","volume":"115","author":"Lieberman","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2020.02.013_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","article-title":"Carboplatin-, oxaliplatin-, and cisplatin\u2013specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy","volume":"1","author":"Caiado","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib31","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2017-10-812461","article-title":"Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies","volume":"131","author":"Curtis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2020.02.013_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JAA.S159411","article-title":"Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers","volume":"11","author":"Jimenez-Rodriguez","year":"2018","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2020.02.013_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ACI.0000000000000435","article-title":"Application of precision medicine to the treatment of anaphylaxis","volume":"18","author":"Labella","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1749-6632.1998.tb08316.x","article-title":"Cytokines and fever: mechanisms and sites of action","volume":"856","author":"Luheshi","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaip.2020.02.013_bib35","first-page":"105","article-title":"Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients","volume":"16","author":"Tonini","year":"2002","journal-title":"J\u00a0Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaip.2020.02.013_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Chen","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jaip.2020.02.013_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.smim.2013.12.003","article-title":"Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development","volume":"26","author":"Waldner","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib38","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cam4.71","article-title":"Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.jaip.2020.02.013_bib39","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.02.013_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2014.0040","article-title":"Chemotherapy hypersensitivity reactions in ovarian cancer","volume":"12","author":"Picard","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jaip.2020.02.013_bib41","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/all.12620","article-title":"Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization","volume":"70","author":"Alvarez-Cuesta","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.02.013_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaip.2014.12.006","article-title":"Hypersensitivity to biological agents\u2014updated diagnosis, management, and treatment","volume":"3","author":"Galv\u00e3o","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.02.013_bib43","doi-asserted-by":"crossref","first-page":"AB41","DOI":"10.1016\/j.jaci.2016.12.191","article-title":"Oxaliplatin induced immune thrombocytopenia in patients with oxaliplatin hypersensitivity: implications for desensitization","volume":"139","author":"Tuttle","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820301720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820301720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:21:31Z","timestamp":1761974491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820301720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S2213219820301720"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.02.013","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}